Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This Study is a Multicenter, Single-arm, Prospective Study to Evaluate the Efficacy and Safety of Drug Discontinuation After Dose Reduction in Ph+CML-CP Patients Threated With 2G-TKI.

NCT05341050 is registered in ClinicalTrials.gov with xuna as lead sponsor.

NCT NCT05341050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05341050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This Study is a Multicenter, Single-arm, Prospective Study to Evaluate the Efficacy and Safety of Drug Discontinuation After Dose Reduction in Ph+CML-CP Patients Threated With 2G-TKI.
Lead sponsor
xuna
Phase
Observational
Overall status
Unknown status
Start date
April 1, 2022
Completion date
May 31, 2026
Enrollment
260 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mmr on 12 month